Clinicopathological Factors and Gastric Cancer Prognosis in the Iranian Population: a Meta-analysis

  • Published : 2015.03.04


Background: Gastric cancer is the most common cancer in the Iranian population. The aim of this study was to determine the effect of clinicopathological factors on prognosis by meta-analysis. Materials and Methods: A literature search was conducted using MEDLINE, EMBASE and Cochrane library and extensive literature search using the Persian databases until February 2011. Prospective follow up studies with multivariate analysis of overall survival of the patients with gastric cancer were included in this review. The data were analyzed by CMA.2. Publication bias are checked by funnel plot and data are shown as Forest plots. Results: From a total of 63 articles, 14 retrospective studies which examined 5 prognostic factors and involving 10,500 patients were included. Tumor size (>35mm) was the main significant factor predicting an unfavorable prognosis for the patients with gastric cancer (RR=1.829, p<0.001) followed by presence of distant metastases (RR=1.607, p<0.001), poor differentiation (RR=1.408, p<0.001) and male sex (RR=1.194, p<0.001). Lymph node metastases (RR=1.058, p=0.698) and moderate differentiation (RR=0.836, p=0.043) were not statistically significant as prognostic factors. Conclusions: This meta-analysis suggests that tumor size>35mm, poor differentiation, presence of distant metastasis and male gender are strongly associated with a poor prognosis in Iranian patients with gastric cancer.


Supported by : Tabriz University of Medical Sciences


  1. Baghestani AR, Hajizadeh E, Fatemi SR (2009). Bayesian analysis for survival of patients with gastric cancer in Iran. Asian Pac J Cancer Prev, 10, 823-6.
  2. Baghestani AR, Hajizadeh E, Fatemi SR (2010a). Application of Bayes method in determining of the risk factors on the survival rate of gastric cancer patients. Koomesh, 11, 129-32.
  3. Baghestani AR, Hajizadeh E, Fatemi SR (2010b). Parametric model to analyse the survival of gastric cancer in the presence of interval censoring. Tumori, 96, 433-7.
  4. Center for disease control and prevention (2013). National Cancer Registry and Report. (2nd ed.) Ministry of Health and Medical Education.
  5. Egger M, Smith GD (2001). Principles and procedures for systematic reviews. Systematic Reviews in Health Care: Meta-analysis in Context. (2nd ed.) London: BMJ.
  6. Eskandar H, Hossein SS, Rahim M, et al (2006). Clinical profile of gastric cancer in Khuzestan, southwest of Iran. World J Gastroenterol, 12, 4832-5.
  7. Ferlay J, Soeriomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancerbase. Lyon: International Agency for resrach on cancer.
  8. Gotoda T, Yanagisawa A, Sasako M, et al (2000). Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer, 3, 219-25.
  9. Hossein S M, Mirinezhad K, Farhang, S, et al (2006). Gastrointestinal cancer occurrence in East Azarbaijan: a five year study from North Western Iran. Asian Pac J Cancer Prev, 7, 309-12.
  10. Hsu PI, Hsieh HL, Lee J, et al (2009). Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol, 16, 1686-94.
  11. Khedmat H, Panahian M, Mashahdian M, Rajabpour MV, Zendehdel K (2011). Prognostic factors and survival in stomach cancer-analysis of 15 years of data from a referral hospital in iran and evaluation of international variation. Onkologie, 34, 178-82.
  12. Kunisaki C, Makino H, Takagawa R, et al (2008). Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol, 15, 1959-67.
  13. Li C, Oh S, Kim S, et al (2009). Risk factors of survival and surgical treatment for advanced gastric cancer with large tumor size. J Gastrointest Surg, 13, 881-5.
  14. Liu X, Xu Y, Long Z, Zhu H, Wang Y (2009). Prognostic Significance of tumor size in T3 gastric cancer. Ann Surg Oncol, 16, 1875-82.
  15. Maruyama K (1987a). The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterology, 22, 63-8.
  16. Micheli A, Ciampichini R, Oberaigner W, et al (2009). The advantage of women in cancer survival: An analysis of EUROCARE-4 data. Europ J Cancer, 45, 1017-27.
  17. Mittal A, Gupta SP, Jhan DK, Sathian B, Poudel B (2013). Impact of various tumor markers in prognosis of gastric cancer. A hospital based study from the tertiary care hospital of Kathmandu valley. Asian Pac J Cancer Prev, 14, 1965-7.
  18. Moghimi-Dehkordi B, Safaee A, Ghiasi S, Zali MR (2009a). Survival in gastric cancer patients: univariate and multivariate analysis. East Afr J Public Health, 6, 41-4.
  19. Moghimi-Dehkordi B, Safaee A, Pourhoseingholi M A, et al (2008). Statistical comparison of survival models for analysis of cancer data. Asian Pac J Cancer Prev, 9, 417-20.
  20. Moghimi-Dehkordi B, Safaee A, Tabei SZ (2009). A comparison between Cox proportional hazard models and logistic regression on prognostic factors in gastric cancer. East Afr J Public Health, 6, 20-2.
  21. Moghimi-Dehkordi B, Safaee A, Zali MR (2009b). Comparison of colorectal and gastric cancer: survival and prognostic factors. Saudi J Gastroenterol, 15, 18-23.
  22. Movahedi M, Afsharfard A, Moradi A, et al (2009). Survival rate of gastric cancer in Iran. J Res Med Sci, 14, 367-73.
  23. Nicholas DR (2000). Men, Masculinity, and cancer: risk-factor behaviors, early detection, and psychosocial adaptation. J American College Health, 49, 27-33.
  24. Pourhoseingholi MA, Hajizadeh E, Abadi A, et al (2009a). Prognostic factors in gastric cancer using log-normal censored regression model. J Gorgan Uni Med Sci, 11, 45-50.
  25. Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, et al (2009b). Prognostic factors in gastric cancer using lognormal censored regression model. Indian J Med Res, 129, 262-7.
  26. Pourhoseingholi MA, Pourhoseingholi A, Vahedi M, et al (2011). Alternatives for Cox regression model: using parametric models to analyze the survival of cancer patients. Iran J Cancer Prev, 1, 1-9.
  27. Rajaeefard A, Moghimi-Dehkordi B, Tabatabaee H, et al (2009). Applying parametric models for survival analysis of gastric cancer. FEYZ, 13, 83-8.
  28. Sadighi S, Raafat J, Mohagheghi M, Meemary F (2005). Gastric carcinoma: 5 year experience of a single institute. Asian Pac J Cancer Prev, 6, 195-6.
  29. Saito H, Osaki T, Murakami D, et al (2006). Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg, 192, 296-300.
  30. Selcukbiricik F, Tural D, Bilici A, et al (2013). Clinicopathological features and localization of gastric cancers and their effects on survival in Turkey. Asian Pac J Cancer Prev, 14, 553-6.
  31. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S (2007). Multivariate prognostic study on large gastric cancer. J Surg Oncol, 96, 14-8.
  32. Somi MH, Farhang S, Mirinezhad SK, et al (2008). Cancer in East Azerbaijan, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev, 9, 327-30.
  33. Tsujitani S, Oka S, Saito H, et al (1999). Less invasive surgery for early gastric cancer based on the low probability of lymph node metastasis. Surg, 125, 148-54.
  34. Wang X, Wan F, Pan J, et al (2008). Tumor size: A nonneglectable independent prognostic factor for gastric cancer. J Surg Oncol, 97, 236-40.
  35. Yokota T, Ishiyama S, Saito T, et al (2004). Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol, 39, 380-4.
  36. Yokota T, Saito T, Teshima S, et al (2001). Probability of lymph node metastasis in small gastric cancer tumor: is it an indication for limited surgery? Int Surg, 86, 206-9.
  37. Yokota T, Saito T, Teshima S, et al (2001). Probability of lymph node metastasis in small gastric cancer tumor: is it an indication for limited surgery? Int Surg, 86, 206-9.
  38. Zeraati H, Mahmoudi M, Kazemnejad A, Mohammad K (2005). Postoperative survival in gastric cancer patients and its associated factors: a method based on a non-homogenous semi-markovian process. Int J Cancer Res, 1, 87-93.

Cited by

  1. Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil vol.16, pp.13, 2015,
  2. Relationship of Amplification and Expression of the C-MYC Gene with Survival among Gastric Cancer Patients vol.16, pp.16, 2015,